



Characteristics and risk factors for post-COVID-19 breathlessness after hospitalisation for COVID-19

Luke Daines¹, Bang Zheng¹, Omer Elneima², Ewen Harrison¹, Nazir I. Lone¹, John R. Hurst³, Jeremy S. Brown³, Elizabeth Sapey⁴, James D. Chalmers⁵, Jennifer K. Quint⁶, Paul Pfeffer⁷, Salman Siddiqui², Samantha Walker⁸, Krisnah Poinasamy⁸, Hamish McAuley², Marco Sereno², Aarti Shikotra², Amisha Singapuri², Annemarie B. Docherty¹, Michael Marks⁹, Mark Toshner¹⁰, Luke S. Howard¹¹, Alex Horsley¹², Gisli Jenkins⁶, Joanna C. Porter³, Ling-Pei Ho¹³, Betty Raman¹⁴, Louise V. Wain¹⁵, Christopher E. Brightling², Rachael A. Evans², Liam G. Heaney¹⁶, Anthony De Souza¹⁷ and Aziz Sheikh¹ on behalf of the PHOSP-COVID Study Collaborative Group¹⁸

¹Usher Institute, University of Edinburgh, Edinburgh, UK. ²The Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, UK. ³UCL Respiratory, University College London, London, UK. ⁴Centre for Translational Inflammation Research, University of Birmingham, Birmingham, UK. ⁵School of Medicine, University of Dundee, Dundee, UK. ⁶National Heart and Lung Institute, Imperial College London, London, UK. ⁷Barts Health NHS Trust and Queen Mary University of London, London, UK. ⁸Asthma + Lung UK, London, UK. ⁹Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK. ¹⁰Heart Lung Research Institute, Department of Medicine, University of Cambridge, Cambridge, UK. ¹¹Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK. ¹²Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK. ¹³MRC Weatherall Institute of Molecular Medicine, Oxford University, Oxford, UK. ¹⁴Radcliffe Department of Medicine, University of Oxford, Oxford, UK. ¹⁵Department of Health Sciences and NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK. ¹⁶Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK. ¹⁷Population Health Science Institute, Newcastle University, Newcastle, UK. ¹⁸Members of the PHOSP-COVID Study Collaborative Group are listed in the supplementary material.

Corresponding author: Aziz Sheikh (aziz.sheikh@ed.ac.uk)



Shareable abstract (@ERSpublications)

Socioeconomic deprivation, pre-existing depression/anxiety, female sex and longer admission duration were risk factors for persistent breathlessness in patients assessed 5 months after hospitalisation for COVID-19 <https://bit.ly/3TnzMq1>

Cite this article as: Daines L, Zheng B, Elneima O, *et al.* Characteristics and risk factors for post-COVID-19 breathlessness after hospitalisation for COVID-19. *ERJ Open Res* 2023; 9: 00274-2022 [DOI: 10.1183/23120541.00274-2022].

Copyright ©The authors 2023

This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.

Received: 7 June 2022
Accepted: 16 Oct 2022

Abstract

Background Persistence of respiratory symptoms, particularly breathlessness, after acute coronavirus disease 2019 (COVID-19) infection has emerged as a significant clinical problem. We aimed to characterise and identify risk factors for patients with persistent breathlessness following COVID-19 hospitalisation.

Methods PHOSP-COVID is a multicentre prospective cohort study of UK adults hospitalised for COVID-19. Clinical data were collected during hospitalisation and at a follow-up visit. Breathlessness was measured by a numeric rating scale of 0–10. We defined post-COVID-19 breathlessness as an increase in score of ≥ 1 compared to the pre-COVID-19 level. Multivariable logistic regression was used to identify risk factors and to develop a prediction model for post-COVID-19 breathlessness.

Results We included 1226 participants (37% female, median age 59 years, 22% mechanically ventilated). At a median 5 months after discharge, 50% reported post-COVID-19 breathlessness. Risk factors for post-COVID-19 breathlessness were socioeconomic deprivation (adjusted OR 1.67, 95% CI 1.14–2.44), pre-existing depression/anxiety (adjusted OR 1.58, 95% CI 1.06–2.35), female sex (adjusted OR 1.56, 95% CI 1.21–2.00) and admission duration (adjusted OR 1.01, 95% CI 1.00–1.02). Black ethnicity (adjusted OR 0.56, 95% CI 0.35–0.89) and older age groups (adjusted OR 0.31, 95% CI 0.14–0.66) were less likely to report post-COVID-19 breathlessness. Post-COVID-19 breathlessness was associated with worse performance on the shuttle walk test and forced vital capacity, but not with obstructive airflow limitation. The prediction model had fair discrimination (concordance statistic 0.66, 95% CI 0.63–0.69) and good calibration (calibration slope 1.00, 95% CI 0.80–1.21).



Conclusions Post-COVID-19 breathlessness was commonly reported in this national cohort of patients hospitalised for COVID-19 and is likely to be a multifactorial problem with physical and emotional components.

Introduction

Coronavirus disease 2019 (COVID-19) continues to have a huge impact internationally [1]. The post-acute COVID-19 syndrome (also known as “long COVID”) usually occurs 3 months from the onset of COVID-19, with symptoms that last for ≥ 2 months and cannot be explained by an alternative diagnosis [2]. The term “long COVID” may also be used to refer to ongoing symptomatic COVID-19 occurring between 4 and 12 weeks after acute COVID-19 infection [3]. With increasing understanding of the debilitating longer-term effects of COVID-19 [4–7], characterising and being able to predict which individuals will suffer from long COVID is a policy priority [8].

Breathlessness is one of the most common and burdensome symptoms reported by individuals, forming part of a complex of respiratory symptoms observed in long COVID [9]. The prevalence of persistent breathlessness in hospitalised and non-hospitalised patients after acute COVID-19 is estimated to be between 26% and 39% [10–14]. Breathlessness is understood as a multidimensional disease concept with different underlying physiological mechanisms including respiratory and cardiovascular diseases, deconditioning, being overweight and emotional factors such as anxiety [15, 16].

In a community-based sample investigating the persistence of symptoms 12 weeks after acute COVID-19, a respiratory-predominant symptom cluster including breathlessness, chest tightness and chest pain was identified [17]. Within this respiratory cluster, a higher proportion of individuals were obese, cigarette smokers, had more comorbidities and considered their acute COVID-19 symptoms severe [17]. In a single-site study of 478 hospital survivors, new-onset dyspnoea was more likely in younger patients, those treated in the intensive therapy unit (ITU) and those with pulmonary embolism [18]; yet another smaller study found no association with dyspnoea at 3 months and ITU admission [19]. A further single-site study of 119 adults hospitalised with severe COVID-19 pneumonia found that failure to return to pre-COVID-19 breathlessness a median 61 days after discharge was associated with comorbid obstructive lung disease, and high scores on anxiety, depression or post-COVID-19 functional status screening, but not ITU admission or inpatient pulmonary embolism [20].

In this study, we sought to estimate the frequency of and characterise risk factors for persisting breathlessness using a multicentre cohort of patients who were discharged following hospitalisation for COVID-19. A secondary aim was to derive a prediction model to identify individuals most at risk of new or worsening breathlessness post-hospitalisation for COVID-19.

Methods

Study design, setting and population

PHOSP-COVID is a multicentre prospective cohort study of adults discharged from one of 53 National Health Service (NHS) hospitals in the UK following admission for COVID-19. Data were collected during hospital admission and at a research visit, between 1 and 8 months after discharge (depending on participant and investigator availability), from clinical health records, and supplemented by questionnaires, clinical and research samples and additional clinical assessments. Participants aged ≥ 18 years who were discharged from hospital following inpatient treatment for COVID-19 based on a positive reverse transcriptase (RT)-PCR test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or clinician diagnosis (if there was a high index of suspicion and testing was either unavailable or considered inaccurate) were included. Individuals were excluded if they attended the emergency department but were not admitted to hospital or had an existing condition with a life expectancy < 6 months. Recruitment occurred between August 2020 and November 2021. Here, we report on the patients who provided data for breathlessness both before COVID-19 and at their first research assessment, before January 2022.

Data collection and outcome

Patient characteristics prior to admission, during hospitalisation and at the research visit were considered. We included patient demographics, patient-reported past medical history, number of comorbidities, body mass index (BMI) and smoking status. Hospital admission data included the level of respiratory support received (categorised based on the World Health Organization clinical progression scale) (supplementary table S1) [21], length of stay, treatments and complications during hospitalisation. At the research visit, patient-reported outcomes were collected using the General Anxiety Disorder-7 Questionnaire (GAD-7) [22], Patient Health Questionnaire-9 (PHQ-9) [23] and Post Traumatic Stress Disorder Checklist (PCL-5) [24]. Results from clinical tests included full blood count,

C-reactive protein, N-terminal pro-B-type natriuretic peptide or B-type natriuretic peptide, lung function tests, and the incremental shuttle walk test (ISWT).

Lung function testing was limited at certain recruiting sites due to COVID-19 restrictions [25]. Forced expiratory volume in 1 s (FEV₁) and forced vital capacity (FVC) were measured in accordance with American Thoracic Society/European Respiratory Society criteria [26] and used to calculate the FEV₁/FVC ratio. Airflow obstruction was defined by an FEV₁/FVC ratio less than the lower limit of normal (LLN). Transfer capacity of the lung for carbon monoxide (T_{LCO}) and carbon monoxide transfer coefficient (K_{CO}) were obtained using the best of two readings. Percent predicted and LLN were calculated using Global Lung Function Initiative equations [27, 28].

At the research visit, participants reported their perceived breathlessness at the time of the visit and recalled their level of breathlessness before developing COVID-19 using a Patient Symptom Questionnaire (PSQ), a numeric rating scale between 0 and 10 (supplementary figure S1). The availability of the PSQ breathlessness score at the time of the research visit and before COVID-19 allowed a new variable to be created, which we defined as “post-COVID-19 breathlessness”; this was used as our primary outcome. In line with JOHNSON *et al.* [29], we took the minimum clinically important difference for a change in breathlessness as 1 point on the 0–10 numeric rating scale. Thus, individuals who rated their breathlessness at the time of the research visit as at least 1 point greater than before developing COVID-19 (*i.e.* they reported new or worsening breathlessness compared to baseline), were categorised as having post-COVID-19 breathlessness. Sensitivity analyses were performed using breathlessness reported at the time of the research visit based on 1) PSQ and 2) Dyspnoea-12 (which was only reported at the research visit) [30].

Statistical analysis

We used descriptive statistics to describe participant characteristics. Continuous variables were presented as means and standard deviations or medians and interquartile ranges, as appropriate. Binary and categorical variables were presented as counts and percentages.

For the primary outcome, we report univariable and multivariable logistic regression with and without imputed data. Continuous explanatory variables were checked for linearity compared with the dependent variable and included with a quadratic term when necessary. Explanatory variables were assessed for multicollinearity. Explanatory variables collected at the research visit were not included in the multivariable model for two reasons. First, the model was intended to make predictions for breathlessness using data available at hospital discharge. Second, due to the multisite nature of the study, certain variables (such as lung function) were likely to be missing at specific sites in a systematic manner, making imputation of these variables inappropriate. Explanatory variables were added to the model manually following initial descriptive analysis (though not based on a p-value threshold) and in consultation with the expert clinical group. Final model selection was based on a criterion-based approach intending to minimise the Akaike Information Criteria (AIC) and maximise the concordance statistic (C-statistic). First-order interactions were checked and included if influential. Under the assumption that missing values within variables were missing at random, we used multiple imputation by chained equations to create 20 datasets each with 10 iterations based on the following variables: sex at birth, age at admission (as a factor), ethnicity, socioeconomic status determined using the Index of Multiple Deprivation (IMD) expressed as quintiles, BMI, number of comorbidities, pre-existing respiratory disease, pre-existing depression or anxiety, admission duration, level of respiratory support, and post-COVID-19 breathlessness. Apparent performance measures of the prediction model were evaluated using the C-statistic, expected/observed number of events (E/O), calibration slope (each calculated using the median from the 20 imputed datasets) and calibration plot (evaluated in the first imputed dataset). To investigate differences between individuals according to the severity of post-COVID-19 breathlessness, multinomial modelling was used in the imputed dataset (supplementary table S2). To assess the associations between clinical measures during the research visit and post-COVID-19 breathlessness, separate multivariable logistic regression models were fitted, adjusting for age, sex, ethnicity and IMD.

We used R (version 3.6.3) for all statistical analysis.

Results

Participants

1843 participants attended a research visit between 1 and 8 months after discharge, of whom 617 had no data for breathlessness and were excluded (figure 1). There were no clear differences between included and excluded participants (supplementary table S3). Of the 1226 participants included in this analysis, 458 (37%) were female and the median age was 59 years (range 21–89 years). 873 (71%) were of white ethnicity (table 1). Median admission duration was 8 days (interquartile range 4–17 days) (table 2). Of




FIGURE 1 Flow diagram of participants. PSQ: patient symptom questionnaire; BNP: B-type natriuretic peptide; NT-pro-BNP: N-terminal pro-BNP.

those with data for RT-PCR, 1039 (85%) had a positive result. 270 (22%) patients required the highest level of respiratory support (*i.e.* invasive mechanical ventilation). 714 (58%) participants were discharged between March and July 2020 (figure 2). There was a higher proportion of missingness for the clinical tests at the research visit (table 3) compared with data collected during hospitalisation.

Main results

615 (50%) participants reported post-COVID-19 breathlessness at the research visit compared to their pre-COVID-19 baseline level, of whom 407 reported no breathlessness (PSQ 0) at baseline (table 1). Females were more likely to report post-COVID-19 breathlessness than males (57% *versus* 46%) (table 1 and supplementary figure S2). There was little difference between individuals with and without post-COVID-19 breathlessness in ethnicity (supplementary figure S3), smoking status, or number of comorbidities including the pre-existence of respiratory or cardiovascular diseases. However, the prevalence of pre-existing depression or anxiety was higher in the group with post-COVID-19 breathlessness (22% *versus* 11%) and those with post-COVID-19 breathlessness had a slightly higher BMI (mean 32.7 *versus* 31.4 kg·m⁻²). Individuals with post-COVID-19 breathlessness had longer hospital admission (median 9 *versus* 7 days), with little or no difference in the level of respiratory support required, medications (including corticosteroids) received or in-hospital complications (table 2).

The multivariable logistic regression identified that post-COVID-19 breathlessness was associated with the most deprived quintile (adjusted OR 1.67, 95% CI 1.14–2.44) (table 4 and figure 3), pre-existing depression/anxiety (adjusted OR 1.58, 95% CI 1.06–2.35), female sex (adjusted OR 1.56, 95% CI 1.21–2.00) and admission duration (adjusted OR 1.01, 95% CI 1.00–1.02 per day). Individuals of Black ethnicity (adjusted OR 0.56, 95% CI 0.35–0.89) were less likely to report post-COVID-19 breathlessness. Compared to 50–59-year-olds, participants aged 60–69 years (adjusted OR 0.70, 95% CI 0.51–0.96), 70–79 years (adjusted OR 0.43, 95% CI 0.28–0.64) and ≥80 years (adjusted OR 0.31, 95% CI 0.14–0.66) were less likely to report post-COVID-19 breathlessness. The level of respiratory support received, pre-existing respiratory disease, number of comorbidities and BMI were not associated with post-COVID-19 breathlessness.

Multinomial modelling

Of the 615 participants with post-COVID-19 breathlessness, 213 (35%) had mild and 402 (65%) had severe breathlessness. Compared to those with no post-COVID-19 breathlessness, severe post-COVID-19 breathlessness was associated with the three most deprived quintiles, female sex, pre-existing depression/anxiety and admission duration (table 5). Individuals of Black ethnicity and those in older age groups were less likely to report severe post-COVID-19 breathlessness. Mild post-COVID-19 breathlessness was associated with having more comorbidities and longer admission duration.

TABLE 1 Patient characteristics

	Total, N (%)	Post-COVID-19 breathlessness		Total
		No	Yes	
Total, N (%)		611 (49.8)	615 (50.2)	1226
Age at admission, years	1213 (98.9)			
<30		10 (1.6)	15 (2.4)	25 (2.0)
30–39		38 (6.2)	41 (6.7)	79 (6.4)
40–49		87 (14.2)	103 (16.7)	190 (15.5)
50–59		151 (24.7)	203 (33.0)	354 (28.9)
60–69		183 (30.0)	174 (28.3)	357 (29.1)
70–79		107 (17.5)	61 (9.9)	168 (13.7)
≥80		29 (4.7)	11 (1.8)	40 (3.3)
Data missing		6 (1.0)	7 (1.1)	13 (1.1)
Sex at birth	1226 (100.0)			
Male		416 (68.1)	352 (57.2)	768 (62.6)
Female		195 (31.9)	263 (42.8)	458 (37.4)
Ethnicity	1203 (98.1)			
White		422 (69.1)	451 (73.3)	873 (71.2)
South Asian		82 (13.4)	71 (11.5)	153 (12.5)
Black		52 (8.5)	40 (6.5)	92 (7.5)
Mixed		17 (2.8)	16 (2.6)	33 (2.7)
Other		27 (4.4)	25 (4.1)	52 (4.2)
Data missing		11 (1.8)	12 (2.0)	23 (1.9)
Index of Multiple Deprivation	1204 (98.2)			
1, most deprived		112 (18.3)	154 (25.0)	266 (21.7)
2		135 (22.1)	131 (21.3)	266 (21.7)
3		116 (19.0)	112 (18.2)	228 (18.6)
4		111 (18.2)	103 (16.7)	214 (17.5)
5, least deprived		127 (20.8)	103 (16.7)	230 (18.8)
Data missing		10 (1.6)	12 (2.0)	22 (1.8)
BMI, kg·m⁻², mean±sd	1090 (88.9)	31.4±7.1	32.7±7.1	32.0±7.1
Smoking	1213 (98.9)			
Never-smokers		350 (57.3)	339 (55.1)	689 (56.2)
Ex-smokers		246 (40.3)	260 (42.3)	506 (41.3)
Current smokers		7 (1.1)	11 (1.8)	18 (1.5)
Data missing		8 (1.3)	5 (0.8)	13 (1.1)
Number of comorbidities, median (IQR)	1226 (100.0)	2.0 (0.0–3.0)	2.0 (1.0–4.0)	2.0 (0.0–3.0)
Pre-existing cardiovascular condition	1226 (100.0)			
No		329 (53.8)	350 (56.9)	679 (55.4)
Yes		282 (46.2)	265 (43.1)	547 (44.6)
Pre-existing respiratory condition	1226 (100.0)			
No		449 (73.5)	444 (72.2)	893 (72.8)
Yes		162 (26.5)	171 (27.8)	333 (27.2)
Pre-existing depression or anxiety	1207 (98.5)			
No		538 (88.1)	471 (76.6)	1009 (82.3)
Yes		66 (10.8)	132 (21.5)	198 (16.2)
Data missing		7 (1.1)	12 (2.0)	19 (1.5)
Breathlessness before COVID-19, PSQ	1226 (100.0)			
0		374 (61.2)	407 (66.2)	781 (63.7)
1–2		103 (16.9)	128 (20.8)	231 (18.8)
≥3		134 (21.9)	80 (13.0)	214 (17.5)

Data are presented as n (%) unless otherwise stated. BMI: body mass index; IQR: interquartile range; PSQ: Patient Symptom Questionnaire.

Prediction model

The multivariable model (equation S1) had fair discriminative ability (C-statistic 0.66, 95% CI 0.63–0.69) (supplementary figure S4) and good calibration (calibration slope 1.00, 95% CI 0.80–1.21; E/O 1.00) despite some under- and over-prediction at higher probabilities (supplementary figure S5).

TABLE 2 Patient characteristics available during hospital admission

	Total, N (%)	Post-COVID-19 breathlessness		Total
		No	Yes	
Total, N (%)		611 (49.8)	615 (50.2)	1226
Admission duration, days, median (IQR)	1225 (99.9)	7.0 (4.0–14.0)	9.0 (4.0–22.0)	8.0 (4.0–17.0)
SARS-CoV-2 PCR result	1137 (92.7)			
Negative		47 (7.7)	51 (8.3)	98 (8.0)
Positive		522 (85.4)	517 (84.1)	1039 (84.7)
Data missing		42 (6.9)	47 (7.3)	89 (7.3)
WHO clinical progression scale	1226 (100.0)			
WHO class 3–4		110 (18.0)	113 (18.4)	223 (18.2)
WHO class 5		252 (41.2)	225 (36.6)	477 (38.9)
WHO class 6		136 (22.3)	120 (19.5)	256 (20.9)
WHO class 7–9		113 (18.5)	157 (25.5)	270 (22.0)
Proning during mechanical ventilation	1102 (89.9)			
No		466 (76.3)	426 (69.3)	892 (72.8)
Yes		87 (14.2)	123 (20.0)	210 (17.1)
Data missing		58 (9.5)	66 (10.7)	124 (10.1)
Pulmonary embolism	1146 (93.5)			
No		518 (84.8)	507 (82.4)	1025 (83.6)
Yes		56 (9.2)	65 (10.6)	121 (9.9)
Data missing		37 (6.1)	43 (7.0)	80 (6.5)
Coronary thrombosis	1140 (93.0)			
No		570 (93.3)	565 (91.9)	1135 (92.6)
Yes		<5	<5	5 (0.4)
Data missing				86 (7.0)
Antibiotic therapy	1187 (96.8)			
No		115 (18.8)	121 (19.7)	236 (19.2)
Yes		477 (78.1)	474 (77.1)	951 (77.6)
Data missing		19 (3.1)	20 (3.3)	39 (3.2)
Systemic steroids, oral or i.v.	1144 (93.3)			
No		319 (52.2)	294 (47.8)	613 (50.0)
Yes		250 (40.9)	281 (45.7)	531 (43.3)
Data missing		42 (6.9)	40 (6.5)	82 (6.7)
Therapeutic dose anticoagulation	1150 (93.8)			
No		352 (57.6)	333 (54.1)	685 (55.9)
Yes		220 (36.0)	245 (39.8)	465 (37.9)
Data missing		39 (6.4)	37 (6.0)	76 (6.2)

Data are presented as n (%) unless otherwise stated. World Health Organization (WHO) clinical progression scale: not requiring continuous supplemental oxygen (levels 3–4); continuous supplemental oxygen only (level 5); continuous positive airway pressure ventilation, bilevel positive airway pressure or high-flow nasal oxygen (level 6); invasive mechanical ventilation, extra-corporeal membrane oxygenation and acute renal replacement therapy (levels 7–9). n<5 and related subtotals have been suppressed. IQR: interquartile range.

Clinical characteristics from the research visit

The period between discharge and research visit was a median 4.7 months (interquartile range 3.4–6.0 months). Fewer participants reviewed between 6 and 8 months after discharge were treated with steroids or antibiotics, and had on average a longer admission duration, and required the highest level of respiratory support compared to individuals who attended a research visit within 6 months of hospitalisation (supplementary tables S4–S6 and figure S6). Despite these differences, the period between discharge and research visit was not associated with post-COVID-19 breathlessness (median 4.7 *versus* 4.7 months; OR 1.00, 95% CI 1.00–1.00) (table 3).

At the research visit, individuals with post-COVID-19 breathlessness had higher scores on the PHQ-9 (median 8.0 *versus* 3.0), GAD-7 (median 5.0 *versus* 2.0) and PCL-5 (median 15.0 *versus* 6.0) than participants without post-COVID-19 breathlessness. With differences in age, sex, ethnicity and socioeconomic status accounted for, individuals with post-COVID-19 breathlessness walked shorter ISWT distances (median 350 *versus* 440 m) with greater leg fatigue afterward (median 3.0 *versus* 2.0) but no difference in oxygen saturations (median 96.0% *versus* 96.0%).




FIGURE 2 Dates of discharge and research visit for the 1226 study participants.

748 (61%) participants completed spirometry at the research visit, with gas transfer available for up to 276 (23%) people. More individuals with post-COVID-19 breathlessness had an FVC less than the LLN (28.0% versus 13.8%) and an FEV₁ less than the LLN (21.5% versus 14.6%). However, there was little difference in the presence of obstructive lung function (based on the LLN of FEV₁/FVC) between those with and without post-COVID-19 breathlessness (3.9% versus 6.9%). K_{CO} was lower in those with post-COVID-19 breathlessness compared to those without (median 99.6% versus 103.5% predicted), while little difference was observed for T_{LCO} (median 90.7% versus 90.1% predicted).

The following measures from the research visit were associated with increased risk of post-COVID-19 breathlessness (table 3): higher total scores on the PHQ-9 (adjusted OR 1.09, 95% CI 1.07–1.12), GAD-7 (adjusted OR 1.07, 95% CI 1.05–1.09) and PCL-5 (adjusted OR 1.03, 95% CI 1.02–1.04), lower haemoglobin level (adjusted OR 0.88, 95% CI 0.79–0.98 per 1 g·dL⁻¹), shorter ISWT distance (adjusted OR 0.91, 95% CI 0.85–0.97 per 100 m), more leg fatigue (adjusted OR 1.14, 95% CI 1.06–1.23), and lower FVC % predicted (adjusted OR 0.98, 95% CI 0.97–0.99).

Sensitivity analyses

Results from the sensitivity analyses were consistent with results from the primary outcome and are described in the supplementary material (supplementary tables S7–S13 and figure S7).

Discussion

In this national cohort of 1226 patients who required hospitalisation for COVID-19, half considered their breathlessness to be new or worsening at the research visit compared to before they had COVID-19. Post-COVID-19 breathlessness was associated with the most deprived quintile, pre-existing depression or anxiety, female sex and longer admission duration. Individuals of Black ethnicity and those aged ≥ 60 years were less likely to report post-COVID-19 breathlessness at follow-up. There was no association between severity of acute COVID-19 and post-COVID-19 breathlessness. At the research visit, participants reporting post-COVID-19 breathlessness had, on average, worse mental health status, lower haemoglobin levels, and walked shorter distances during and had greater leg fatigue after the ISWT. Individuals with post-COVID-19 breathlessness were more likely to have an FEV₁ and FVC below the LLN compared to those with no change or improvement in breathlessness. However, there was no clear association with T_{LCO} or airflow obstruction. Sensitivity analyses supported the primary findings.

Our results have similarities with a French cohort of 478 adults evaluated 3 months after hospitalisation for COVID-19, who found that participants with new or worsening dyspnoea were, on average, younger, and had a longer hospital admission and little or no difference in pulmonary function tests compared to those

TABLE 3 Patient characteristics available at the research visit

	Total, N (%)	Post-COVID-19 breathlessness		Total	OR (95% CI)
		No	Yes		
Total, N (%)		611 (49.8)	615 (50.2)	1226	
Discharge to review period, months	1226 (100.0)	4.7 (3.4–6.0)	4.7 (3.3–6.0)	4.7 (3.4–6.0)	1.00 (1.00–1.00)
Breathlessness at research visit, PSQ	1226 (100.0)				
0		462 (75.6)	0 (0.0)	462 (37.7)	
1–2		70 (11.5)	143 (23.3)	213 (17.4)	
≥3		79 (12.9)	472 (76.7)	551 (44.9)	
PHQ-9 total score	1188 (96.9)	3.0 (1.0–8.0)	8.0 (3.0–13.0)	5.0 (2.0–11.0)	1.09 (1.07–1.12)
GAD-7 total score	1187 (96.8)	2.0 (0.0–6.0)	5.0 (1.0–11.0)	3.0 (0.0–8.0)	1.07 (1.05–1.09)
PCL-5 total severity score	1184 (96.6)	6.0 (2.0–15.0)	15.0 (5.0–31.2)	9.0 (3.0–23.0)	1.03 (1.02–1.04)
CRP, mg·L⁻¹	800 (65.3)	4.0 (1.4–5.0)	4.0 (2.0–5.0)	4.0 (1.8–5.0)	1.01 (0.99–1.04)
BNP/NT-pro-BNP above threshold	642 (52.4)				0.65 (0.32–1.33)
No		293 (48.0)	304 (49.4)	597 (48.7)	
Yes		29 (4.7)	16 (2.6)	45 (3.7)	
Haemoglobin, g·dL⁻¹	861 (70.2)	14.4 (13.3–15.2)	14.0 (13.1–15.0)	14.2 (13.2–15.2)	0.88 (0.79–0.98)
Males	537 (43.8)	14.7 (13.9–15.6)	14.6 (13.6–15.5)	14.7 (13.8–15.5)	0.90 (0.79–1.03)
Females	324 (26.4)	13.5 (12.8–14.3)	13.4 (12.6–14.0)	13.4 (12.7–14.1)	0.80 (0.65–0.99)
ISWT distance, m	737 (60.1)	440.0 (270.0–615.0)	350.0 (230.0–540.0)	380.0 (257.5–570.0)	0.91 (0.85–0.97) [#]
ISWT, % predicted	658 (53.7)	60.5 (42.0–81.9)	52.5 (35.1–71.2)	56.3 (37.9–75.9)	0.99 (0.98–1.00)
Oxygen saturations post-ISWT, %	727 (59.3)	96.0 (94.0–98.0)	96.0 (94.0–98.0)	96.0 (94.0–98.0)	0.98 (0.94–1.02)
Borg leg fatigue score post-ISWT	722 (58.9)	2.0 (0.5–3.0)	3.0 (2.0–4.0)	3.0 (1.0–4.0)	1.14 (1.06–1.23)
FEV₁, L	748 (61.0)	2.8 (2.3–3.4)	2.7 (2.2–3.3)	2.8 (2.2–3.3)	0.96 (0.81–1.15)
FEV₁, % predicted	683 (55.7)	93.9 (83.4–105.7)	89.9 (77.9–101.3)	91.7 (79.7–103.7)	1.00 (0.99–1.00)
FEV₁ <LLN	683 (55.7)				1.61 (1.05–2.45)
No		274 (85.4)	284 (78.5)	558 (81.7)	
Yes		47 (14.6)	78 (21.5)	125 (18.3)	
FVC, L	746 (60.8)	3.6 (2.9–4.3)	3.3 (2.6–4.0)	3.5 (2.8–4.2)	0.70 (0.57–0.86)
FVC, % predicted	681 (55.5)	93.7 (83.0–105.4)	86.8 (74.5–98.5)	90.0 (78.2–102.4)	0.98 (0.97–0.99)
FVC <LLN	681 (55.5)				2.43 (1.60–3.70)
No		276 (86.2)	260 (72.0)	536 (78.7)	
Yes		44 (13.8)	101 (28.0)	145 (21.3)	
FEV₁/FVC ratio, %	736 (60.0)	79.4 (73.9–84.0)	81.6 (77.3–86.0)	80.6 (76.0–85.5)	1.04 (1.02–1.06)
FEV₁/FVC <LLN	673 (54.9)				0.58 (0.28–1.19)
No		295 (93.1)	342 (96.1)	637 (94.7)	
Yes		22 (6.9)	14 (3.9)	36 (5.3)	
T_{LCO}, mmol·min⁻¹·kPa⁻¹	272 (22.2)	7.6 (6.4–8.7)	6.8 (5.8–8.3)	7.3 (6.1–8.4)	0.94 (0.83–1.07)
T_{LCO}, % predicted	252 (20.6)	90.1 (78.6–102.7)	90.7 (74.2–104.2)	90.7 (76.8–103.2)	0.99 (0.99–1.00)
T_{LCO} <80% predicted	252 (20.6)				1.48 (0.79–2.77)
No		86 (72.3)	90 (67.7)	176 (69.8)	
Yes		33 (27.7)	43 (32.3)	76 (30.2)	
K_{CO}, mmol·min⁻¹·kPa⁻¹·L⁻¹	276 (22.5)	1.5 (1.3–1.6)	1.5 (1.2–1.7)	1.5 (1.3–1.6)	0.49 (0.18–1.29)
K_{CO}, % predicted	259 (21.1)	103.5 (92.6–108.7)	99.6 (87.4–112.3)	101.8 (89.2–110.1)	0.99 (0.97–1.00)
K_{CO} <80% predicted	259 (21.1)				1.43 (0.53–3.88)
No		112 (92.6)	127 (92.0)	239 (92.3)	
Yes		9 (7.4)	11 (8.0)	20 (7.7)	

Data are presented as median (interquartile range) or n (%), unless otherwise stated. PSQ: Patient Symptom Questionnaire; PHQ-9: Patient Health Questionnaire-9; GAD-7: General Anxiety Disorder-7; PCL-5: Post Traumatic Stress Disorder Checklist; CRP: C-reactive protein; BNP: B-type natriuretic peptide; NT-pro-BNP: N-terminal pro-BNP; ISWT: incremental shuttle walk test; FEV₁: forced expiratory volume in 1 s; LLN: lower limit of normal; FVC: forced vital capacity; T_{LCO}: transfer capacity of the lung for carbon monoxide; K_{CO}: carbon monoxide transfer coefficient. #: refers to the risk of worsening breathlessness for each 100 m achieved.

without new/worsening dyspnoea [18]. In addition, and in keeping with our findings, having a pre-existing respiratory condition was not associated with post-COVID-19 breathlessness [18], which may be explained by individuals with chronic lung disease being used to a background level of breathlessness, which was not considered worse following COVID-19.

In contrast to our study, JUTANT *et al.* [18] found that individuals with new/worsening dyspnoea were more likely to have required ITU treatment and have a pulmonary embolism during the admission. Participants

TABLE 4 Multivariable logistic regression for post-COVID-19 breathlessness

	Post-COVID-19 breathlessness		OR (95% CI)		
	No	Yes	Univariable	Multivariable	Multiple imputation
Sex at birth					
Male	416 (54.2)	352 (45.8)	1 (ref)	1 (ref)	1 (ref)
Female	195 (42.6)	263 (57.4)	1.59 (1.26–2.01) (p<0.001)	1.44 (1.10–1.90) (p=0.009)	1.56 (1.21–2.00) (p=0.001)
Age at admission, years					
<30	10 (40.0)	15 (60.0)	1.12 (0.49–2.63) (p=0.795)	1.20 (0.47–3.12) (p=0.706)	1.35 (0.57–3.23) (p=0.498)
30–39	38 (48.1)	41 (51.9)	0.80 (0.49–1.31) (p=0.378)	0.83 (0.48–1.44) (p=0.511)	0.86 (0.51–1.44) (p=0.568)
40–49	87 (45.8)	103 (54.2)	0.88 (0.62–1.26) (p=0.482)	0.96 (0.64–1.44) (p=0.832)	0.96 (0.66–1.40) (p=0.832)
50–59	151 (42.7)	203 (57.3)	1 (ref)	1 (ref)	1 (ref)
60–69	183 (51.3)	174 (48.7)	0.71 (0.53–0.95) (p=0.022)	0.62 (0.44–0.88) (p=0.007)	0.70 (0.51–0.96) (p=0.025)
70–79	107 (63.7)	61 (36.3)	0.42 (0.29–0.62) (p<0.001)	0.41 (0.26–0.64) (p<0.001)	0.43 (0.28–0.64) (p<0.001)
≥80	29 (72.5)	11 (27.5)	0.28 (0.13–0.57) (p=0.001)	0.27 (0.11–0.60) (p=0.002)	0.31 (0.14–0.66) (p=0.003)
Index of Multiple Deprivation					
5, least deprived	127 (55.2)	103 (44.8)	1 (ref)	1 (ref)	1 (ref)
4	111 (51.9)	103 (48.1)	1.14 (0.79–1.66) (p=0.480)	1.30 (0.85–1.99) (p=0.220)	1.22 (0.82–1.81) (p=0.328)
3	116 (50.9)	112 (49.1)	1.19 (0.82–1.72) (p=0.352)	1.21 (0.80–1.84) (p=0.365)	1.22 (0.82–1.79) (p=0.327)
2	135 (50.8)	131 (49.2)	1.20 (0.84–1.71) (p=0.321)	1.31 (0.87–1.96) (p=0.195)	1.20 (0.82–1.76) (p=0.338)
1, most deprived	112 (42.1)	154 (57.9)	1.70 (1.19–2.42) (p=0.004)	1.87 (1.24–2.84) (p=0.003)	1.67 (1.14–2.44) (p=0.009)
Ethnicity					
White	422 (48.3)	451 (51.7)	1 (ref)	1 (ref)	1 (ref)
South Asian	82 (53.6)	71 (46.4)	0.81 (0.57–1.14) (p=0.231)	0.83 (0.55–1.26) (p=0.378)	0.80 (0.55–1.17) (p=0.244)
Black	52 (56.5)	40 (43.5)	0.72 (0.46–1.11) (p=0.137)	0.57 (0.34–0.95) (p=0.031)	0.56 (0.35–0.89) (p=0.015)
Mixed	17 (51.5)	16 (48.5)	0.88 (0.44–1.77) (p=0.720)	0.98 (0.44–2.20) (p=0.956)	0.85 (0.41–1.75) (p=0.656)
Other	27 (51.9)	25 (48.1)	0.87 (0.49–1.52) (p=0.616)	0.84 (0.44–1.62) (p=0.606)	0.80 (0.44–1.44) (p=0.448)
BMI, kg·m⁻²	31.4±7.1	32.7±7.1	1.03 (1.01–1.04) (p=0.002)	1.08 (0.97–1.21) (p=0.164)	1.08 (0.98–1.19) (p=0.107)
Number of comorbidities	2.0±2.0	2.4±2.3	1.09 (1.03–1.15) (p=0.002)	1.09 (1.00–1.18) (p=0.049)	1.08 (1.00–1.17) (p=0.049)
Pre-existing respiratory condition					
No	449 (50.3)	444 (49.7)	1 (ref)	1 (ref)	1 (ref)
Yes	162 (48.6)	171 (51.4)	1.07 (0.83–1.37) (p=0.611)	0.85 (0.62–1.17) (p=0.312)	0.82 (0.61–1.11) (p=0.195)
Pre-existing depression or anxiety					
No	538 (53.3)	471 (46.7)	1 (ref)	1 (ref)	1 (ref)
Yes	66 (33.3)	132 (66.7)	2.28 (1.66–3.16) (p<0.001)	1.54 (1.00–2.38) (p=0.050)	1.58 (1.06–2.35) (p=0.026)
Admission duration, days	13.2±17.2	17.2±22.2	1.01 (1.00–1.02) (p=0.001)	1.01 (1.00–1.02) (p=0.064)	1.01 (1.00–1.02) (p=0.002)
WHO clinical progression scale					
WHO class 3–4	110 (49.3)	113 (50.7)	1 (ref)	1 (ref)	1 (ref)
WHO class 5	252 (52.8)	225 (47.2)	0.87 (0.63–1.19) (p=0.388)	0.88 (0.61–1.29) (p=0.522)	0.84 (0.60–1.18) (p=0.314)
WHO class 6	136 (53.1)	120 (46.9)	0.86 (0.60–1.23) (p=0.407)	0.90 (0.58–1.38) (p=0.619)	0.80 (0.54–1.18) (p=0.260)
WHO class 7–9	113 (41.9)	157 (58.1)	1.35 (0.95–1.93) (p=0.097)	1.17 (0.70–1.98) (p=0.548)	0.92 (0.57–1.47) (p=0.715)

Data are presented as n (%) or mean±SD, unless otherwise stated. The dependent variable was post-COVID-19 breathlessness. World Health Organization (WHO) clinical progression scale: not requiring continuous supplemental oxygen (levels 3–4); continuous supplemental oxygen only (level 5); continuous positive airway pressure ventilation, bilevel positive airway pressure or high-flow nasal oxygen (level 6); invasive mechanical ventilation, extra-corporeal membrane oxygenation and acute renal replacement therapy (levels 7–9). The logistic regression model also included body mass index (BMI)².

in the study by JUTANT *et al.* [18] had similarities to participants in our cohort, in respect to median age (61 years), sex (58% male) and the proportion who were diagnosed with pulmonary embolism (9.1%). However, a much greater proportion were intubated (51%), compared to 22% of patients in our study. Prior to COVID-19, HERRIDGE *et al.* [31] found that patients (median age 44 years, 41% without comorbidities) admitted to the ITU with acute respiratory distress syndrome were likely to have ongoing limitations in exercise capacity due to ventilator-induced lung injury, skeletal muscle wasting and deconditioning. Therefore, it might be anticipated that severity of COVID-19 be associated with post-COVID-19 breathlessness. Our cohort was older and with more comorbidities than the sample studied by HERRIDGE *et al.* [31] and fewer participants were intubated than the participants reported by JUTANT *et al.* [18]. Therefore, a possible explanation for the lack of association observed between severity of acute COVID-19 and post-COVID-19 breathlessness in our study may be that those not admitted to the ITU had poor pre-morbid health and were more liable to suffer from acute deconditioning than those admitted to the ITU.

Post-COVID-19 breathlessness OR (95% CI, p-value)

Sex at birth	Male	
	Female	1.56(1.21–2.00, p=0.001)
Age at admission (years)	50–59	
	<30	1.35(0.57–3.23, p=0.498)
	30–39	0.86 (0.51–1.44, p=0.568)
	40–49	0.96 (0.66–1.40, p=0.832)
	60–69	0.70 (0.51–0.96, p=0.025)
	70–79	0.43 (0.28–0.64, p<0.001)
Index of Multiple Deprivation	≥80	0.31 (0.14–0.66, p=0.003)
	5, least deprived	
	4	1.22 (0.82–1.81, p=0.328)
	3	1.22 (0.82–1.79, p=0.327)
	2	1.20 (0.82–1.76, p=0.338)
Ethnicity	1, most deprived	1.67 (1.14–2.44, p=0.009)
	White	
	South Asian	0.80 (0.55–1.17, p=0.244)
	Black	0.56 (0.35–0.89, p=0.015)
	Mixed	0.85 (0.41–1.75, p=0.656)
BMI (kg·m ⁻²)	Other	0.80 (0.44–1.44, p=0.448)
		1.08 (0.98–1.19, p=0.107)
Number of comorbidities		1.08 (1.00–1.17, p=0.049)
	Respiratory	
Depression or anxiety	No	0.82 (0.61–1.11, p=0.195)
	Yes	1.58 (1.06–2.35, p=0.026)
Admission duration (days)	Yes	1.01 (1.00–1.02, p=0.002)
WHO clinical progression scale	WHO class 3–4	
	WHO class 5	0.84 (0.60–1.18, p=0.314)
	WHO class 6	0.80 (0.54–1.18, p=0.260)
	WHO class 7–9	0.92 (0.57–1.47, p=0.715)




FIGURE 3 Multivariable logistic regression for post-COVID-19 breathlessness. BMI: body mass index; WHO: World Health Organization.

Our analyses suggest that post-COVID-19 breathlessness was not associated with objective measures of airflow obstruction and, therefore, less likely to be a consequence of new airway disease. Similarly, we did not see an excess of restrictive patterns in those with post-COVID-19 breathlessness. Individuals with post-COVID-19 breathlessness had, on average, a lower FVC, which may suggest an element of interstitial disease. In the smaller number of individuals who underwent gas transfer tests, K_{CO} % predicted was lower in those with post-COVID-19 breathlessness compared to those without, but when adjusted for age, sex, ethnicity and IMD, the association with post-COVID-19 breathlessness was not statistically significant (*i.e.* the confidence intervals overlapped with the null value), making the possibility of fibrosis difficult to confirm. We consider it likely that several factors may have contributed to this observation. Firstly, pulmonary vascular involvement (*e.g.* pulmonary embolism and its sequelae) can contribute to ongoing breathless after acute COVID-19 in the absence of an ongoing clot burden [32]. One possibility is that some individuals with post-COVID-19 breathlessness had subclinical pulmonary emboli during admission [32]. The possible influence of selection bias should also be recognised. Although we aimed to have all patients undertaking all procedures as per protocol, access to more complex lung function tests such as gas transfer was limited and may have resulted in those with clinical features suggesting an interstitial process being more likely to have undergone these tests.

Post-COVID-19 breathlessness was more likely in the most deprived socioeconomic group. Physical activity levels are known to be lowest in the most deprived groups [33], so deprivation may have led to a low exercise tolerance phenotype that was compounded by acute and chronic sequelae of COVID-19. Obesity is also associated with deprivation, as well as chronic breathlessness [16, 34]. Whilst obesity was not associated with post-COVID-19 breathlessness, the mean BMI of this sample was 32.0 kg·m⁻², which may be an additional contributing factor to the experience of breathlessness. We speculate that post-COVID-19 breathlessness is likely to be a multifactorial and, therefore, heterogeneous problem, which may consist of a decrement in lung function in combination with anxiety or depression, deconditioning,

TABLE 5 Multinomial modelling for post-COVID-19 breathlessness

	Post-COVID-19 breathlessness OR (95% CI)	
	Mild	Severe
Sex at birth		
Male	1 (ref)	1 (ref)
Female	1.34 (0.95–1.88)	1.67 (1.26–2.22)
Age at admission, years		
<30	2.22 (0.78–6.33)	0.95 (0.35–2.62)
30–39	1.23 (0.62–2.43)	0.68 (0.38–1.22)
40–49	1.38 (0.84–2.26)	0.78 (0.51–1.18)
50–59	1 (ref)	1 (ref)
60–69	0.79 (0.51–1.23)	0.64 (0.46–0.91)
70–79	0.44 (0.25–0.80)	0.39 (0.25–0.62)
≥80	0.58 (0.23–1.41)	0.13 (0.04–0.44)
Index of Multiple Deprivation		
5, least deprived	1 (ref)	1 (ref)
4	1.14 (0.68–1.90)	1.26 (0.79–2.00)
3	1.05 (0.63–1.74)	1.38 (0.88–2.18)
2	0.82 (0.49–1.36)	1.52 (0.99–2.35)
1, most deprived	1.02 (0.61–1.71)	2.22 (1.44–3.44)
Ethnicity		
White	1 (ref)	1 (ref)
South Asian	0.80 (0.49–1.33)	0.74 (0.48–1.14)
Black	1.02 (0.61–1.71)	0.46 (0.27–0.80)
Mixed	0.76 (0.27–2.15)	0.88 (0.39–1.98)
Other	0.88 (0.39–1.96)	0.77 (0.39–1.49)
BMI, kg·m ⁻²	0.99 (0.96–1.02)	1.01 (0.99–1.04)
Number of comorbidities	1.12 (1.02–1.24)	1.06 (0.98–1.16)
Pre-existing respiratory condition		
No	1 (ref)	1 (ref)
Yes	0.94 (0.64–1.39)	0.76 (0.55–1.07)
Pre-existing depression or anxiety		
No	1 (ref)	1 (ref)
Yes	1.41 (0.83–2.38)	1.64 (1.06–2.54)
Admission duration, days	1.01 (1.00–1.02)	1.02 (1.01–1.02)
WHO clinical progression scale		
WHO class 3–4	1 (ref)	1 (ref)
WHO class 5	0.92 (0.59–1.45)	0.81 (0.55–1.20)
WHO class 6	0.76 (0.45–1.31)	0.83 (0.53–1.30)
WHO class 7–9	0.90 (0.48–1.69)	0.98 (0.58–1.65)

The dependent variable was post-COVID-19 breathlessness categorised into three levels, No/Mild/Severe. The reference group (not shown) were those with no post-COVID-19 breathlessness (n=611). Mild post-COVID-19 breathlessness: n=213; severe post-COVID-19 breathlessness: n=402. World Health Organization (WHO) clinical progression scale: not requiring continuous supplemental oxygen (levels 3–4); continuous supplemental oxygen only (level 5); continuous positive airway pressure ventilation, bilevel positive airway pressure or high-flow nasal oxygen (level 6); invasive mechanical ventilation, extra-corporeal membrane oxygenation and acute renal replacement therapy (levels 7–9). BMI: body mass index.

poor exercise tolerance, fatigue and lower haemoglobin. Post-COVID-19 breathlessness may also be influenced by central nervous system perception [35] and whilst we did not collect data specifically to confirm or refute this hypothesis, JUTANT *et al.* [18] found that a greater proportion of individuals reporting new or worsening breathlessness scored highly on the Nijmegen questionnaire [36], suggesting a component of dysfunctional breathing.

Regarding interventions for post-COVID-19 breathlessness, our findings suggest that screening for and addressing both the physical and emotional components of breathlessness are likely to be important. In a randomised controlled trial of a 6-week online breathing and wellbeing programme, PHILIP *et al.* [37] demonstrated improvements in mental health and aspects of breathlessness in people with ongoing symptoms after COVID-19. Interestingly, the intervention led to improvements in the affective, rather than the physical component of the Dyspnoea-12 score, which may suggest that changes in breathlessness

experience were related to the emotional impact of the wellbeing programme. Other rehabilitation programmes, which have tended to focus on physical conditioning, have also been shown to improve breathlessness [35, 38], walking distance, lower limb strength and health-related quality of life in patients with persisting symptoms after COVID-19 [35, 38, 39], though corroboration of these results in larger trials would be valuable.

PHOSP-COVID is one of the largest cohorts of post-hospitalisation COVID-19 survivors in the world with comprehensive assessment of participants providing information on physical, psychological, and biochemical characteristics and exposures [6, 7]. This analysis included participants discharged between March 2020 and 31 March 2021, meaning patients treated in hospital both before and after changes in clinical practice for COVID-19 patients (*e.g.* the use of oral steroids [40] or proning during mechanical ventilation [41]) were represented. Limitations include the lack of viral genomic sequencing, vaccination and lung imaging data, which meant that we could not account for vaccination status, radiological abnormalities [18, 19] or the influence that infection with different genetic strains of SARS-CoV-2 may have on post-COVID-19 breathlessness [42]. Participants in this study represent a small proportion of the total number of patients discharged from hospital after treatment for COVID-19 in the UK, which may affect the generalisability of the results. Furthermore, participants in this study were younger than in another, larger sample of hospitalised COVID-19 patients [43], and only included individuals able to attend the research visit. Predicting the influence of this potential selection bias is challenging, because while more severely affected individuals may be underrepresented, it is conceivable that those with ongoing symptoms may have been more willing to participate.

We chose to use patient-reported breathlessness from the PSQ as the primary outcome because it provided a measure of breathlessness both before and after admission for COVID-19. We wanted to account for pre-existing breathlessness in our analyses because being able to identify participants whose breathlessness was new or worsening after COVID-19 was most important to inform policymakers and health services. We acknowledge that as the PSQ breathlessness score before COVID-19 was recorded at the research visit, patient responses may be considered subjective and liable to recall bias. Nevertheless, as the sensitivity analyses supported the associations identified with the primary outcome, we feel that recall bias or subjectivity related to the PSQ breathlessness score has not unduly influenced the main findings. The model derived in this analysis has the potential to predict the probability that an individual discharged following treatment for COVID-19 will experience post-COVID-19 breathlessness. However, a limitation of our work is the lack of model validation, which should be addressed before the prediction model is used.

The multicentre nature of the study and workload pressures on sites meant the period between discharge and follow-up varied. The heterogeneity introduced by considering patient-reported breathlessness from different periods is likely to influence how individuals reported breathlessness, with those reviewed later since hospital discharge having longer time to recover. Compared to individuals who attended a research visit within 6 months of discharge, a higher proportion of participants attending the research visit ≥ 6 months after discharge had a longer admission duration and required higher levels of respiratory support. A possible explanation for this observation is that the majority of participants attending 6–8 months after hospitalisation were discharged before July 2020 (supplementary figure S6), and were therefore treated earlier in the pandemic and before the use of oral steroids was widespread [40]. However, overall, there was no difference in the period between discharge and the research visit between those reporting post-COVID-19 breathlessness and those not.

In conclusion, post-COVID-19 breathlessness was common in this national cohort of patients hospitalised for COVID-19. Our analysis indicates that individuals discharged following COVID-19 who are from deprived backgrounds, females, <70 years of age, with pre-existing depression or anxiety and who had an admission of over a week, are at greatest risk of new or worsening breathlessness post-COVID-19.

Provenance: Submitted article, peer reviewed.

Acknowledgements: This study and the PHOSP-COVID consortium are supported by a grant to the University of Leicester from the MRC-UK Research and Innovation and the Department of Health and Social Care (DHSC) through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19. The NIHR Leicester Biomedical Research Centre is a partnership between the University Hospitals of Leicester National Health Service Trust, the University of Leicester and Loughborough University. The study was also supported by the Health Data Research UK Breathe Hub. This study would not be possible without all the participants who have given their time and support. We thank all the participants and their families. We thank the many research

administrators, healthcare and social-care professionals who contributed to setting up and delivering the study at all of the 65 NHS trusts/Health Boards and 25 research institutions across the UK, as well as all the supporting staff at the NIHR Clinical Research Network, NIHR Biomedical Research Centres, Health Research Authority, Research Ethics Committee, DHSC, Public Health Scotland and Public Health England, and support from the ISARIC Coronavirus Clinical Characterisation Consortium. We thank Kate Holmes at the NIHR Office for Clinical Research Infrastructure (NOCRI) for her support in coordinating the charities group. The PHOSP-COVID industry framework was formed to provide advice and support in commercial discussions, and we thank the Association of the British Pharmaceutical Industry as well as Ivana Poparic and Peter Sargent at NOCRI for coordinating this. We are very grateful to all the charities that have provided insight to the study: Action Pulmonary Fibrosis, Alzheimer's Research UK, Asthma + Lung UK, British Heart Foundation, Diabetes UK, Cystic Fibrosis Trust, Kidney Research UK, MQ Mental Health, Muscular Dystrophy UK, Stroke Association Blood Cancer UK, McPin Foundations, and Versus Arthritis. We thank the NIHR Leicester Biomedical Research Centre patient and public involvement group and the Long Covid Support Group. The authors would like to acknowledge the support of the eDRIS Team (Public Health Scotland) for their involvement in obtaining approvals, provisioning, and linking data and the use of the secure analytical platform within the National Safe Haven. The views expressed in the publication are those of the authors and not necessarily those of the National Health Service, MRC-UK, NIHR or DHSC.

This study is registered at www.isrctn.com with identifier number ISRCTN10980107. The protocol, consent form, definition and derivation of clinical characteristics and outcomes, training materials, regulatory documents, information about requests for data access, and other relevant study materials are available online. Please see <https://phosp.org/> for more information.

Ethics approval, study registration and role of the funders: The PHOSP-COVID study received ethical approval from the Leeds West Research Ethics Committee (20/YH/0225) and was registered with the ISRCTN Registry (ISRCTN10980107). All participants provided written informed consent. The funders had no role in study design, data collection/analysis, or report writing.

Author contributions: The manuscript was initially drafted by L. Daines, B. Zheng and A. Sheikh, and further developed by the writing group. R.A. Evans, A. Horsley, M. Toshner, J.S. Brown, P. Pfeffer, L-P. Ho, J.D. Chalmers, M. Marks, H. McAuley, M. Sereno, A. Shikotra and A. Singapuri made substantial contributions to the acquisition of data. L. Daines, B. Zheng, A. Sheikh, C.E. Brightling, R.A. Evans, L.V. Wain, O. Elneima, H. McAuley, A. Shikotra, A. De Soyza, G. Jenkins, L.S. Howard, A. Horsley, M. Toshner, P. Pfeffer, L-P. Ho, J.D. Chalmers, M. Marks, E. Harrison, A.B. Docherty, A. Singapuri, N.I. Lone and L.G. Heaney made substantial contributions to the conception and design of the work. All authors contributed to data interpretation and critical review and revision of the manuscript. L. Daines, B. Zheng and A. Sheikh verified all the data in the study and had final responsibility for the decision to submit the article for publication.

Conflict of interest: C.E. Brightling, A. Shikotra and M. Sereno report grants from UKRI-MRC/DHSC-NIHR during the conduct of the study. J.D. Chalmers reports grants and personal fees from AstraZeneca and BI, personal fees from Chiesi, grants from Gilead Sciences, grants and personal fees from GSK and Insmed, personal fees from Janssen, grants and personal fees from Novartis, and personal fees from Zambon outside the submitted work, and is an associate editor of this journal. A. De Soyza reports grants, personal fees and other support from AstraZeneca, Bayer, BI, Chiesi, Forest Labs, GSK, Grifols, Insmed, MedImmune, Novartis, Pfizer and 30T outside the submitted work. R.A. Evans reports grants from UKRI/MRC/NIHR during the conduct of the study and speaker fees from BI. A. Horsley reports funding from NIHR Manchester Biomedical Research Centre, grants from the Cystic Fibrosis Foundation, JP Moulton Trust and NIHR, and personal fees from Vertex Pharmaceuticals and Mylan Healthcare, all outside the submitted work. L.G. Heaney reports support from AstraZeneca, BI, Chiesi, GSK and Napp Pharmaceuticals, personal fees from Novartis, Hoffman la Roche/Genentech Inc., Sanofi, Evelo Biosciences, GSK, AstraZeneca, Teva, Theravance and Circassia, grants from Medimmune, Novartis UK, Roche/Genentech Inc and GSK, Amgen, Genetech/Hoffman la Roche, AZ, Medimmune, GSK, Aerocrine and Vitalograph, outside the submitted work. J.R. Hurst reports grants, personal fees and nonfinancial support from pharmaceutical companies that make medicines to treat respiratory disease, outside the submitted work. G. Jenkins reports grants from GSK, grants and personal fees from Pliant Therapeutics, and grants from Biogen, during the conduct of the study; personal fees from Galapagos, other support from Galecto, personal fees and other support from GSK and AstraZeneca, personal fees from Boehringer Ingelheim, Pliant, Bristol Myers Squibb, Chiesi and Roche/Promedior, personal fees and other support from RedX, other support from NuMedii and Nordic Biosciences, personal fees from Veracyte, PatientMPower, Resolution Therapeutics and Vicore, outside the submitted work; and is supported by a National Institute of Health Research Professorship (NIHR ref. RP-2017-08-ST2-014) and is trustee for Action for Pulmonary Fibrosis. P. Pfeffer reports grants from NIHR outside the submitted work. J.K. Quint reports grants and personal fees from AstraZeneca, grants from Bayer, grants and personal fees from BI, Chiesi and GSK, grants from MRC, The Health Foundation and AUK/BLF, outside the submitted work. B. Raman is supported by the British Heart

Foundation Oxford Centre of Research Excellence (RE/18/3/34214). A. Sheikh reports grants from HDRUK, NIHR, MRC and ICSF, during the conduct of the study; and is a Member of the Scottish Government's CMO COVID-19 Advisory Group and Standing Committee on Pandemics. A. Singapuri reports grants from MRC during the conduct of the study. S. Siddiqui reports grants from NIHR Leicester Biomedical Research Centre and NIHR PHOSP COVID, personal fees from AstraZeneca, GSK, CSL Behring, Knopp Biosciences, Owlstone Medical and Chiesi, outside the submitted work; and has a patent pending for volatile breath biomarkers of breathlessness. M. Toshner reports personal fees from Actelion/J&J and GSK, and other support from Morphogen-IX, outside the submitted work. L.V. Wain reports grants from GSK and Orion, outside the submitted work. All other authors declare no competing interests.

Support statement: PHOSP-COVID is supported by a grant from the MRC-UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19 (grant references MR/V027859/1 and COV0319). Core funding was provided by NIHR Leicester Biomedical Research Centre to support the PHOSP-COVID coordination team and NIHR Biomedical Research Centres, Clinical Research Facilities and NIHR Health Protection Research Unit, and Translational Research Collaborations networks across the country. The study was also supported by the UK Health Data Research BREATHE Hub. Funding information for this article has been deposited with the Crossref Funder Registry.

References

- 1 World Health Organization. COVID-19 Weekly Epidemiological Update. <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-june-2022>. Date last updated: 1 June 2022. Date last accessed: 1 June 2022.
- 2 Soriano JB, Murthy S, Marshall JC, *et al*. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis* 2021; 22: E102–E107.
- 3 National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188]. <https://www.nice.org.uk/guidance/ng188>. Date last updated: 11 November 2021. Date last accessed: 7 June 2022.
- 4 Huang C, Huang L, Wang Y, *et al*. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet* 2021; 397: 220–232.
- 5 Huang L, Yao Q, Gu X, *et al*. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. *Lancet* 2021; 398: 747–758.
- 6 Evans RA, McAuley H, Harrison EM, *et al*. Physical, cognitive, and mental health impacts of COVID-19 following hospitalisation – a multi-centre prospective cohort study. *Lancet Respir Med* 2021; 9: 1275–1287.
- 7 Evans RA, Leavy OC, Richardson M, *et al*. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. *Lancet Respir Med* 2022; 10: 761–775.
- 8 Adeloje D, Elneima O, Daines L, *et al*. The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. *Lancet Respir Med* 2021; 9: 1467–1478.
- 9 Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 June 2022. <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/latest>. Date last updated: 1 June 2022. Date last accessed: 7 June 2022.
- 10 Lopez-Leon S, Wegman-Ostrosky T, Perelman C, *et al*. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *Sci Rep* 2021; 11: 16144.
- 11 Fernandez-de-Las-Penas C, Palacios-Cena D, Gomez-Mayordomo V, *et al*. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. *Eur J Intern Med* 2021; 92: 55–70.
- 12 Iqbal FM, Lam K, Sounderajah V, *et al*. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. *EClinicalMedicine* 2021; 36: 100899.
- 13 Cares-Marambio K, Montenegro-Jiménez Y, Torres-Castro R, *et al*. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. *Chron Respir Dis* 2021; 18: 14799731211002240.
- 14 Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. *JAMA Netw Open* 2021; 4: e2111417.
- 15 Lansing RW, Gracely RH, Banzett RB. The multiple dimensions of dyspnea: review and hypotheses. *Respir Physiol Neurobiol* 2009; 167: 53–60.
- 16 Bowden JA, To TH, Abernethy AP, *et al*. Predictors of chronic breathlessness: a large population study. *BMC Public Health* 2011; 11: 33.
- 17 Whitaker M, Elliott J, Chadeau-Hyam M, *et al*. Persistent COVID-19 symptoms in a community study of 606,434 people in England. *Nat Commun* 2022; 13: 1957.

- 18 Jutant EM, Meyrignac O, Beurnier A, *et al.* Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome. *ERJ Open Res* 2022; 8: 00479-2021.
- 19 Lerum TV, Aaløkken TM, Brønstad E, *et al.* Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19. *Eur Respir J* 2021; 57: 2003448.
- 20 D'Cruz RF, Waller MD, Perrin F, *et al.* Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia. *ERJ Open Res* 2021; 7: 00655-2020.
- 21 WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis* 2020; 20: e192–e197.
- 22 Johnson SU, Ulvenes PG, Øktedalen T, *et al.* Psychometric properties of the general anxiety disorder 7-item (GAD-7) scale in a heterogeneous psychiatric sample. *Front Psychol* 2019; 10: 1713.
- 23 Levis B, Benedetti A, Thombs BD. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. *BMJ* 2019; 365: l1476.
- 24 Blevins CA, Weathers FW, Davis MT, *et al.* The posttraumatic stress disorder checklist for DSM-5 (PCL-5): development and initial psychometric evaluation. *J Trauma Stress* 2015; 28: 489–498.
- 25 World Health Organization. Scientific brief. Transmission of SARS-CoV-2: implications for infection prevention precautions. 2020. <https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions>. Date last updated: 9 July 2020. Date last accessed: 7 June 2022.
- 26 Graham BL, Steenbruggen I, Miller MR, *et al.* Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. *Am J Respir Crit Care Med* 2019; 200: e70–e88.
- 27 Quanjer PH, Stanojevic S, Cole TJ, *et al.* Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012; 40: 1324–1343.
- 28 Stanojevic S, Graham BL, Cooper BG, *et al.* Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians. *Eur Respir J* 2017; 50: 1700010.
- 29 Johnson MJ, Bland JM, Oxberry SG, *et al.* Clinically important differences in the intensity of chronic refractory breathlessness. *J Pain Symptom Manage* 2013; 46: 957–963.
- 30 Yorke J, Moosavi SH, Shuldham C, *et al.* Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. *Thorax* 2010; 65: 21–26.
- 31 Herridge MS, Tansey CM, Matté A, *et al.* Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med* 2011; 364: 1293–1304.
- 32 Dhawan RT, Gopalan D, Howard L, *et al.* Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. *Lancet Respir Med* 2021; 9: 107–116.
- 33 NHS Digital. Statistics on Obesity, Physical Activity and Diet. Part 5: Physical activity. 8 May 2019. <https://digital.nhs.uk/data-and-information/publications/statistical/statistics-on-obesity-physical-activity-and-diet/statistics-on-obesity-physical-activity-and-diet-england-2019/part-5-adult-physical-activity> Date last accessed: 12 September 2022.
- 34 NHS Digital. Health survey for England 2018. Overweight and obesity. 3 December 2019. <https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/2018/summary#overweight-and-obesity> Date last accessed: 12 September 2022.
- 35 Bouteleux B, Henrot P, Ernst R, *et al.* Respiratory rehabilitation for Covid-19 related persistent dyspnoea: a one-year experience. *Respir Med* 2021; 189: 106648.
- 36 Van Dixhoorn J, Folgering H. The Nijmegen Questionnaire and dysfunctional breathing. *ERJ Open Res* 2015; 1: 00001-2015.
- 37 Philip KE, Owles H, McVey S, *et al.* An online breathing and wellbeing programme (ENO Breathe) for people with persistent symptoms following COVID-19: a parallel-group, single-blind, randomised controlled trial. *Lancet Respir Med* 2022; 10: 851–862.
- 38 Curci C, Negrini F, Ferrillo M, *et al.* Functional outcome after inpatient rehabilitation in postintensive care unit COVID-19 patients: findings and clinical implications from a real-practice retrospective study. *Eur J Phys Rehabil Med* 2021; 57: 443–450.
- 39 Li J, Xia W, Zhan C, *et al.* A telerehabilitation programme in post-discharge COVID-19 patients (TERECO): a randomised controlled trial. *Thorax* 2021; 77: 697–706.
- 40 The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 – preliminary report. *N Engl J Med* 2021; 384: 693–704.
- 41 Koeckerling D, Barker J, Mudalige NL, *et al.* Awake prone positioning in COVID-19. *Thorax* 2020; 75: 833–834.
- 42 Sheikh A, McMenamin J, Taylor B, *et al.* SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet* 2021; 397: 2461–2462.
- 43 Docherty AB, Harrison EM, Green CA, *et al.* Features of 20,133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* 2020; 369: m1985.